Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DA-3803
- Development stage
- Phase 3
- Lead developer
- Dong-A Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
DA-3803 is a **biosimilar of recombinant human chorionic gonadotropin (r-hCG)** developed for the induction of ovulation and final follicular maturation in women undergoing assisted reproductive technologies. It is produced in Chinese hamster ovary cells and mimics the activity of endogenous hCG, which acts through **luteinizing hormone/choriogonadotropin receptor (LHCGR)** and **follicle-stimulating hormone receptor (FSHR)** to trigger ovulation and luteinization. Phase 1 and Phase 3 studies have demonstrated comparable safety, tolerability, and bioequivalence to the reference product Ovidrel, with similar efficacy in ovulation induction[1][2][4][10]. DA-3803 is used as a single subcutaneous injection and is well-tolerated[1][2][4].
- Brand names
- DA-3803DA3803DA 3803
- Other names
- choriogonadotropin alfa biosimilarrecombinant human chorionic gonadotropinr-hCG
02
Targets
LHCGR (Luteinizing hormone/choriogonadotropin receptor)FSHR (Follicle-stimulating hormone receptor)
Beyond the preview
Go deeper on DA-3803.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DA-3803.